<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220570</url>
  </required_header>
  <id_info>
    <org_study_id>8669-050</org_study_id>
    <nct_id>NCT01220570</nct_id>
  </id_info>
  <brief_title>The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)</brief_title>
  <official_title>A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will evaluate whether treatment with ridaforolimus, dalotuzumab, or
      ridforolimus/dalotuzumab combination therapy reduces Growth Factor Signature (GFS) Score
      among participants with breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The population mean change from baseline in GFS (Growth Factor Signature) score</measure>
    <time_frame>Baseline and Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The population mean change from baseline in Ki67 among participants receiving ridaforolimus/dalotuzumab combination therapy</measure>
    <time_frame>Baseline and Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between change in Ki67 expression and change in GFS after two weeks of treatment with ridaforolimus/dalotuzumab (MK-8669/MK-0646) combination therapy, ridaforolimus (MK-8669) monotherapy and/or dalotuzumab (MK-0646) monotherapy</measure>
    <time_frame>Baseline and Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ridaforolimus + Dalotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ridaforolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ridaforolimus (MK-8669)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalotuzumab (MK-0646)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ridaforolimus + Dalotuzumab</intervention_name>
    <description>Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks</description>
    <arm_group_label>Ridaforolimus + Dalotuzumab</arm_group_label>
    <other_name>MK-8669, MK-0646</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ridaforolimus</intervention_name>
    <description>Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets</description>
    <arm_group_label>Ridaforolimus</arm_group_label>
    <other_name>MK-8669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalotuzumab</intervention_name>
    <description>Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks</description>
    <arm_group_label>Dalotuzumab</arm_group_label>
    <other_name>MK-0646</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has operable Stage I-IIIa invasive breast cancer of the following subtype:
             ER-positive, HER2-negative tumor with histologic grade 2 or 3 and Ki67 â‰¥ 15%

          -  Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam

          -  Participant consents to provide an existing tissue sample or to have a core needle
             biopsy before drug administration

          -  Participant consents to provide tissue samples following drug administration by a
             second core needle biopsy or from a surgical specimen

          -  Participant must have adequate organ function

        Exclusion Criteria:

          -  Participant has received any prior chemotherapy, biological therapy or radiotherapy
             for breast cancer

          -  Participant has a known hypersensitivity to the components of study drugs or their
             analogs, including hypersensitivity to macrolide antibiotics (e.g. clarithromycin,
             erythromycin, azithromycin).

          -  Participant has poorly controlled diabetes mellitus, or requires insulin for glucose
             control.

          -  Participant is unable to swallow capsules and/or absorb oral medications

          -  Participant is pregnant or breastfeeding, or expecting to conceive children within the
             projected duration of the study.

          -  Participant is known to be Human Immunodeficiency Virus (HIV)-positive

          -  Participant has known history of active Hepatitis B or C.

          -  Participant is concurrently using growth hormone (GH) or growth hormone inhibitors

          -  Participant has significant or uncontrolled cardiovascular disease, including heart
             failure, unstable angina, or a myocardial infarction within the last 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Brazil</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <last_update_submitted>January 19, 2015</last_update_submitted>
  <last_update_submitted_qc>January 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>ridaforolimus</keyword>
  <keyword>ridaforolimus/dalotuzumab combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

